Stepping on Roche's toes, Merck cuts into SCLC niche with second-line Keytruda OK

In the increasingly crowded checkpoint race, small cell lung cancer has been a rare area where Roche, a second runner-up, has a lead over the entrenched leaders Merck and Bristol-Myers Squibb. But Merck is finally making some headway in that direction with the latest approval for its PD-1 star.